Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price545.42 USD
Fair value606.79
Ethical score70.0/100
Value readUndervaluedas of 3 Nov 2026
Our investment reviews on this name
2026-11-03Read Distribution540.08+1.0% to today Accumulation gives way to Distribution
2026-11-01Read Accumulation563.81-3.3% to today Markup gives way to Accumulation after an 8% slide in 3 weeks
2026-10-11Read Markup609.64-10.5% to today Distribution gives way to Markup first Markup read since September
2026-10-02Read Distribution609.64-10.5% to today ✓Markup gives way to Distribution first Distribution read since July
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ubiquiti Inc holds its Distribution at $545.42. Consolidating, no directional conviction, held for 12 days.
As held on the ledger · 2026-11-03
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 12 days
Price at the screen
$545.42
Valuation
34.41 trailing · 27.86 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.34
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
20.28%
Below 33%
Interest-bearing debt is just 20.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
26.89%
Below 49%
Money owed to the company is 26.9% of assets, under the 49% limit.
Pass
Revenue purity
0.01%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Ubiquiti clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 20%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when UI's ethical verdict changes
Today UI passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 3 Nov 2026: it trades at roughly a 10% discount to our $606.79 fair value, narrow competitive moat, 23.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. A 10.1% discount to the base estimate.
Where our models see it going: fair-value estimate $606.79, with a range of $440.10 to $697.81, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
A 24%-growth business trading at just 27.9x forward earnings, with a narrow competitive moat and minimal debt. That is a 10% discount to our $606.79 fair value: the market is pricing it cautiously while the fundamentals argue otherwise.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UI trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Distribution$545.42+1.0%Entry 19
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$563.81+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 7.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$606.71+0.7%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$602.71+1.9%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$591.48-3.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826.
2026-10-11Markup · changed$609.64+0.0%Entry 12
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826.
2026-09-24Markup · changed$586.17+3.3%Entry 10
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 15% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $826.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
